← Leaderboards
William James Adams
Brigham And Women'S Hospital
$2,113,532
Attributed
$3,786,569
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2010–23$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,786,569 · 4
By mechanism
R44$2,804,643 · 1
R41$541,432 · 1
R43$317,243 · 1
F31$123,251 · 1
Top collaborators
- Guillermo Garcia-Cardena7 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Frank A Scheer$22,110,197
- Francisco J. Quintana$15,804,456
- Julie E Buring$63,823,301
- Rong Tian$29,765,984
- Mark W Feinberg$27,862,974
Others in their field
Top investigators on “Vascular Endothelium”
- Jan E Schnitzer · Sidney Kimmel Cancer Center$30,139,798
- Michael Simons · Yale University$25,641,903
- Douglas R Seals · University Of Colorado$24,153,936
- Asrar B. Malik · University Of Illinois At Chicago$22,482,141
- Vladimir R Muzykantov · University Of Pennsylvania$21,989,714
- Luisa Iruela-Arispe · Northwestern University$21,370,881
Research focus
Vascular EndotheliumEndotheliumStrokeBlood VesselsPhenotypeRisk FactorsAtherosclerosisResponseMyocardial InfarctionResistanceAtherogenesisAtheroprotectiveBaseEventInsightSmall MoleculeEndothelial DysfunctionProgramsLocationHypertensionCellsInflammationLaboratoriesDrug Discovery
Grant awards (12)
Pharmacological induction of KLF2 and reversal of endothelial dysfunction for the treatment of hypertension$6,500
R43 · FY2023 · HL · contact PI
Pharmacological induction of KLF2 and reversal of endothelial dysfunction for the treatment of hypertension$310,743
R43 · FY2022 · HL · contact PI
Therapeutic Reversal of Endothelial Dysfunction in Atherogenesis$697,873
R44 · FY2018 · HL · contact PI
Therapeutic Reversal of Endothelial Dysfunction in Atherogenesis$1,229,878
R44 · FY2017 · HL · contact PI
Therapeutic Reversal of Endothelial Dysfunction in Atherogenesis$19,598
R44 · FY2017 · HL · contact PI
Therapeutic Reversal of Endothelial Dysfunction in Atherogenesis$857,294
R44 · FY2016 · HL · contact PI
Pharmacological Targeting of Endothelial Dysfunction in Atherogenesis$292,909
R41 · FY2014 · HL · contact PI
Pharmacological Targeting of Endothelial Dysfunction in Atherogenesis$3,398
R41 · FY2014 · HL · contact PI
Pharmacological Targeting of Endothelial Dysfunction in Atherogenesis$245,125
R41 · FY2013 · HL · contact PI
Premature Aging, Vascular Disease and Endothelial Mechanotransduction$41,468
F31 · FY2012 · AG · contact PI
Premature Aging, Vascular Disease and Endothelial Mechanotransduction$40,592
F31 · FY2011 · AG · contact PI
Premature Aging, Vascular Disease and Endothelial Mechanotransduction$41,191
F31 · FY2010 · AG · contact PI